Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.

Authors:
Hogarty MD; Ziegler DS; Franson A; Chi YY; Tsao-Wei D and 13 more

Journal:
Br J Cancer

Publication Year: 2024

DOI:
10.1038/s41416-023-02525-2

PMCID:
PMC10912730

PMID:
38200233

Journal Information

Full Title: Br J Cancer

Abbreviation: Br J Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This work was supported by National Cancer Institute Grant P01 CA081403, St. Baldrick’s Foundation, V Foundation for Cancer Research, Department of Defense Grant CA1702571, Alex’s Lemonade Stand Foundation and ALSF Center of Excellence, Hyundai Hope on Wheels, the Kids Cancer Project, Australian Lions Children’s Cancer Research Fund and an anonymous donor. Open access funding provided by SCELC, Statewide California Electronic Library Consortium."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025